The CEACAM5 drugs market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer and the increasing number of CEACAM5 that ...

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by ...

Oncotarget recently published "Heterogeneity of CEACAM5 in breast cancer" which reported that Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to ...

SAN DIEGO — The novel antibody-drug conjugate tusamitamab ravtansine (tusa rav, Sanofi) did not demonstrate greater efficacy than docetaxel in treating advanced nonsquamous non–small cell lung cancer ...

The carcinoembryonic antigen (CEA) family represents one of the most divergent group of glycoproteins in mammals with respect to sequence and structure (Zimmermann, 1998; Hammarström, 1999). The human ...

Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate ...

Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting CEACAM5, a solid tumour marker expressed across several high‑unmet‑need cancers ...

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. This is an ASCO Meeting Abstract from the 2020 ...